WallStreetZenWallStreetZen

NASDAQ: BRTX
Biorestorative Therapies Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their BRTX stock forecasts and price targets.

Forecast return on equity

Is BRTX forecast to generate an efficient return?

Company
3,409.9%
Industry
95.51%
Market
175.55%
BRTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BRTX forecast to generate an efficient return on assets?

Company
2,223.39%
Industry
28.06%
BRTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BRTX earnings per share forecast

What is BRTX's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.50
Avg 2 year Forecast
-$0.41
Avg 3 year Forecast
-$0.42

BRTX revenue forecast

What is BRTX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$1.4M+300.42%
Avg 2 year Forecast
$2.4M+559.18%
Avg 3 year Forecast
$3.2M+790.83%
BRTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BRTX revenue growth forecast

How is BRTX forecast to perform vs Biotechnology companies and vs the US market?

Company
107.65%
Industry
33.61%
Market
13.79%
BRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BRTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BRTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BRTX$0.35N/AN/A
MTVA$1.74$20.00+1,049.43%Buy
CURX$0.32N/AN/A
CVM$1.08N/AN/A
BOLT$4.56$14.50+217.98%Strong Buy
View Top Biotech Stocks

Biorestorative Therapies Stock Forecast FAQ

What is BRTX's earnings growth forecast for 2026-2028?

(NASDAQ: BRTX) Biorestorative Therapies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.65%.

Biorestorative Therapies's earnings in 2026 is -$11,056,581.On average, 4 Wall Street analysts forecast BRTX's earnings for 2026 to be -$12,863,928, with the lowest BRTX earnings forecast at -$16,479,280, and the highest BRTX earnings forecast at -$8,828,186. On average, 4 Wall Street analysts forecast BRTX's earnings for 2027 to be -$10,525,032, with the lowest BRTX earnings forecast at -$12,983,675, and the highest BRTX earnings forecast at -$7,758,103.

In 2028, BRTX is forecast to generate -$10,654,971 in earnings, with the lowest earnings forecast at -$12,234,617 and the highest earnings forecast at -$8,828,186.

If you're new to stock investing, here's how to buy Biorestorative Therapies stock.

What is BRTX's revenue growth forecast for 2026-2028?

(NASDAQ: BRTX) Biorestorative Therapies's forecast annual revenue growth rate of 107.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.

Biorestorative Therapies's revenue in 2026 is $357,870.On average, 4 Wall Street analysts forecast BRTX's revenue for 2026 to be $36,510,218, with the lowest BRTX revenue forecast at $7,740,268, and the highest BRTX revenue forecast at $66,880,196. On average, 4 Wall Street analysts forecast BRTX's revenue for 2027 to be $60,103,003, with the lowest BRTX revenue forecast at $37,452,910, and the highest BRTX revenue forecast at $83,593,876.

In 2028, BRTX is forecast to generate $81,224,406 in revenue, with the lowest revenue forecast at $62,421,517 and the highest revenue forecast at $100,333,033.

What is BRTX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BRTX) forecast ROA is 2,223.39%, which is higher than the forecast US Biotechnology industry average of 28.06%.

What is BRTX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BRTX) Biorestorative Therapies's current Earnings Per Share (EPS) is -$1.07. On average, analysts forecast that BRTX's EPS will be -$0.50 for 2026, with the lowest EPS forecast at -$0.65, and the highest EPS forecast at -$0.35. On average, analysts forecast that BRTX's EPS will be -$0.41 for 2027, with the lowest EPS forecast at -$0.51, and the highest EPS forecast at -$0.30. In 2028, BRTX's EPS is forecast to hit -$0.42 (min: -$0.48, max: -$0.35).

What is BRTX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BRTX) forecast ROE is 3,409.9%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.